Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808871 · ClinicalTrials.gov registry record · Phase 2
Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)
A Phase 2 study of Rheumatoid Arthritis Interstitial Lung Disease, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
- 20
- Study locations
NCT02808871 is a Phase 2 study of Rheumatoid Arthritis Interstitial Lung Disease that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 123 participants. The trial reports 20 study locations across 20 states.
The verdict
NCT02808871, a Phase 2 study of Rheumatoid Arthritis Interstitial Lung Disease, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pirfenidone
Study Locations (20)
Alabama
- University of Alabama Site at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Colorado
- National Jewish Health - Denver
Florida
- University of Miami - Miami
Louisiana
- Tulane Medical Center - New Orleans
Maryland
- John Hopkins Medicine - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2021-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02808871
The ClinicalTrials.gov registry entry for NCT02808871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis Interstitial Lung Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02808871 reports 20 study locations spanning 20 distinct geographic areas - top geographies include Alabama, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02808871 about?
NCT02808871 is a clinical study titled "Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)". The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.
What is the current status of trial NCT02808871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2017-04-07. Estimated completion is 2021-04-07.
What conditions does trial NCT02808871 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis Interstitial Lung Disease.
What interventions are being tested in trial NCT02808871?
The interventions under investigation include: Placebo (DRUG), Pirfenidone (DRUG).
Who is sponsoring clinical trial NCT02808871?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02808871 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.